Immuneering (Nasdaq: IMRX) is a late-stage oncology company developing a new class of cancer therapies called Deep Cyclic Inhibitors, which are designed to deliver pulsed pathway inhibition faster than tumors can adapt, while having less impact on healthy cells, supporting sustained tumor reduction with improved tolerability. Our lead candidate, atebimetinib, is an oral, once-daily Deep Cyclic Inhibitor of MEK advancing to a pivotal Phase 3 trial in first-line pancreatic cancer, with additional combination studies planned in lung cancer. Backed by deep biological insights and strong Phase 2a data, Immuneering’s Deep Cyclic Inhibitors provide a scalable foundation for therapies across a wide range of cancers.
